The 2025 BioHealth Capital Region Crab Trap Competition will take place on September 24 at 2:00 PM during the Forum at US Pharmacopeia. Nearly 70 applications were received from around the world, and six innovative finalists will pitch for a prize package including $10,000 in cash, $25,000 in IT and cybersecurity services from InfoPathways, and $10,000 in CRO services from Noble Life Sciences and Accelevir. Don’t miss one of the week’s most exciting sessions.

Read more to see who the finalists are this year!

Thanks to a frenzy of grantmaking activity during August, the National Institutes of Health looks, for the first time this year, like it might be able to spend its entire $47 billion budget before the Sept. 30 deadline. After lagging by billions of dollars throughout the spring and summer due to pauses in grant proposal evaluations, agency-wide layoffs, and new layers of political review, the NIH now appears on track to award close to the full tranche of taxpayer money appropriated by Congress.

A STAT analysis shows...

COLUMBIA, Md., (September 10, 2025) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $500,000 Venture Funds investment in CoolTech. TEDCO’s Venture Funds are dedicated to funding and empowering the next generation of early-stage businesses in the state.

“We are in late-stage clinical testing of a breakthrough thermal neuromodulation device for home treatment of migraine, a debilitating neurological disease that afflicts 1 billion people worldwide” said Steven Schaefer, CEO of CoolTech. “Through TEDCO’s support, we have been able to advance our research and development efforts; and are targeting a product launch next year.”

The 2025 BioHealth Capital Region Investment Conference takes place on September 25 at US Pharmacopeia in Rockville, MD, and it is the premier venue for connecting innovative biohealth startups with venture capital, strategic investors, and industry partners. With more than 150 participants already registered, including over 60 companies and 40 investors, this year’s conference will feature curated 1:1 partnering meetings, dynamic quick-pitch sessions, and targeted networking designed to spark collaboration and investment. Whether you are raising capital or scouting the next big opportunity, this is the place to be. Register today!

GAITHERSBURG, Md., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that a contract modification has been executed in the amount of $56 million to supply ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) to the U.S. government. Deliveries are expected to begin this month. This brings the total projected sales for ACAM2000® vaccine and ancillary products to more than $120 million this year from a diverse base of customers. ACAM2000® is licensed for active immunization against smallpox and mpox disease for persons determined to be at high risk for smallpox or mpox infection.

“Our new contract modification for ACAM2000® vaccine...

Be part of the 11th Annual BioHealth Capital Region Forum, September 23–24, 2025, at US Pharmacopeia in Rockville, MD. This year’s theme, Where Human and Artificial Intelligence Converge in the BioHealth Industry, will explore groundbreaking advances shaping the future of healthcare. Connect with industry leaders, investors, government, and academia, and gain insights you can apply to your own organization.

Attendance is free thanks to our sponsors, but space is limited — secure your spot today.

Enjoy live music by The Impurities at the Wednesday evening reception on September 24 at USP. The band features USP team members showcasing their talent outside the lab, including Ron Piervincenzi, Ph.D., CEO, on guitar, Scott Bolgiano on guitar and backing vocals, John Daly on drums, Tim Greiner on lead vocals and harmonica, Alyssa Lang on vocals and saxophone, and Horacio Pappa on keyboards. It is a fun way to connect with peers after a full day of sessions.— register today for the Forum:

COLUMBIA, Md., (September 9, 2025) — TEDCO, Maryland’s economic engine for technology companies, announced a recent $500,000 Pre-Seed Builder Fund investment in Kubanda Cryotherapy. Under the umbrella of TEDCO’s Social Impact Funds, the Pre-Seed Builder Fund invests in and provides support to Maryland-based technology companies led by founders from economically underserved backgrounds.

“We are excited to continue increasing access to care in the veterinary tumor market,” said Bailey Surtees, CEO and co-founder, Kubanda Cryotherapy. “We deeply appreciate TEDCO’s continued support and investment in Maryland’s entrepreneurial ecosystem.”

GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M. Richardson to the role of Chief Commercial Officer, effective September 16, 2025. Ms. Richardson joins the Company with more than 30 years of experience in sales and marketing, commercial, corporate and business development across a range of therapeutic areas, including metabolic disease, hepatology, cardiovascular and addiction medicine. During her career, she has led multiple product launches, built successful commercial franchises and contributed to a variety of business development transactions.

BALTIMORE, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Longeviti Neuro Solutions, a neurotechnology company with a focus on innovative platform solutions for complex brain disorders, today announces the appointment of Tim Scannell, former President & COO of Stryker Corporation, as Chair of its Board of Directors. The company also reveals a $10 million strategic capital partnership with Soleus Capital to accelerate hiring, product development, and medical education efforts in the United States and abroad.

Scannell brings a wealth of experience in the medical device market having served in leadership positions with Stryker Corporation for over thirty years. He advanced from sales and marketing to executive leadership roles highlighted by ten years as Group President of MedSurg & Neurotechnology and three years as President and COO of Stryker. He was responsible for assisting in the selection and development of the strategies and talent that delivered over the last three decades and continues to deliver outstanding results today.